製品名
Naloxone, United States Pharmacopeia (USP) Reference Standard
SMILES string
N1([C@H]2[C@]3([C@@]4([C@@H](Oc5c4c(ccc5O)C2)C(=O)CC3)CC1)O)CC=C
InChI
1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
InChI key
UZHSEJADLWPNLE-GRGSLBFTSA-N
grade
pharmaceutical primary standard
API family
naloxone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Naloxone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Naloxone Hydrochloride
- Naloxone Hydrochloride Injection
- Pentazocine and Naloxone Tablets
- Buprenorphine and Naloxone Sublingual Tablets
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Nina Eriksen et al.
International journal of stroke : official journal of the International Stroke Society, 9(6), 802-810 (2012-08-30)
Strokes have both ischemic and hemorrhagic components, but most studies of experimental stroke only address the ischemic component. This is likely because investigations of hemorrhagic transformation are hindered by the lack of methods based on unbiased principles for volume estimation.
Marco Lanza et al.
British journal of pharmacology, 171(15), 3693-3701 (2014-04-25)
CR4056 is a novel imidazoline-2 (I2 ) ligand exhibiting potent analgesic activity in animal models of pain. In this study, we investigated the effects of CR4056 in a well-established model of postoperative pain where rats develop hyperalgesia in the injured
Daisuke Yamada et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 1852-1860 (2014-02-13)
Although the underlying mechanism remains unknown, several studies have suggested benefits of n-3 long-chain polyunsaturated fatty acid (PUFA) for patients with anxiety disorders. Elevated fear is thought to contribute to the pathogenesis of particular anxiety disorders. The aim of the
Prabhat Singh et al.
Psychopharmacology, 232(2), 465-475 (2014-07-26)
Opiate exposure for longer duration develops state of dependence in humans and animals, which is revealed by signs and symptoms of withdrawal precipitated by opioid receptor antagonists. The sudden withdrawal of opioids produces a withdrawal syndrome in opioid-dependent subjects. Insulin
Ana M Torres-Guzman et al.
Arthritis research & therapy, 16(2), R64-R64 (2014-03-13)
Clinical and preclinical studies have shown that supplementation with ω-3 polyunsaturated fatty acids (ω-3 PUFAs) reduce joint destruction and inflammation present in rheumatoid arthritis (RA). However, the effects of individual ω-3 PUFAs on chronic arthritic pain have not been evaluated
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）